Graham designs, manufactures and sells equipment for the energy, defense and chemical/petrochemical industries. The company designs and manufactures custom-engineered ejectors, vacuum pumping systems, surface condensers and vacuum systems. The company is also a nuclear code accredited fabrication and specialty machining company which provides products to the commercial nuclear utility industry. The company's products are used in a range of industrial process applications, primarily in energy markets, including: petroleum refining, defense, chemical and petrochemical processing, power generation /alternative energy, and other.

Live Oak Bancshares is a bank holding company. Through its subsidiary, Live Oak Banking Company (the Bank), the company is engaged in providing lending and deposit related services. The company directly or indirectly holds the following wholly-owned subsidiaries: Canapi Advisors, LLC, which provides investment advisory services; Live Oak Ventures, Inc., which invests in businesses that align with the company's initiative in financial technology; Live Oak Grove, LLC, which provides an on-site restaurant location; Government Loan Solutions, Inc., which is a management and technology consulting firm; and 504 Fund Advisors, LLC, which serves as the investment advisor to the 504 Fund, a closed-end mutual fund.

Nicholas Financial is a holding company. Through its subsidiary, Nicholas Financial, Inc., the company is engaged primarily in acquiring and servicing automobile finance installment contracts (Contracts) for purchases of used and new automobiles and light trucks. In addition, the company also originates direct consumer loans (Direct Loans) and sells consumer-finance related products. For Automobile Finance Business - Contracts, the company is engaged in the business of providing financing programs, on behalf of purchasers of used cars and light trucks. For Contract Procurement, the Contracts purchased by the company is for used vehicles. For Direct Loans, the loans originated directly between the company and the consumer.

Pennymac Financial Services is a holding company. Through its subsidiaries, the company is a financial services firm with a mortgage platform and integrated business focused on the production and servicing residential mortgage loans and the management of investments related to mortgage market. The company's segments are: production, which performs mortgage loan origination, acquisition and sale activities; servicing, which performs loan servicing for both newly originated loans the company is holding for sale and loans the company services for others; and investment management, which represents the company's investment management activities, which include the activities associated with investment asset acquisitions.

SBA Communications is a holding company. Through its subsidiaries, the company is an owner and operator of wireless communications infrastructure, including tower structures, rooftops, and other structures that support antennas used for wireless communications. The company's operations are in the U.S. and its territories. In its site leasing business, the company leases antenna space to wireless service providers on towers that the company owns or operates and manages rooftop and tower sites for property owners under various contractual arrangements. In its site development business, the company assists wireless service providers in developing and maintaining their own wireless service networks.

Turning Point Therapeutics is a clinical-stage biopharmaceutical company designing and developing novel small molecule, targeted oncology therapies. The company develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-na?ve and TKI-pretreated patients. The company's main drug candidate is repotrectinib (TPX-0005). In addition to repotrectinib, the company's pipeline includes two clinical-stage multi-targeted kinase inhibitors, TPX-0022 (a MET/CSF1R/SRC inhibitor) and TPX-0046 (a RET/SRC inhibitor), and a preclinical ALK inhibitor, TPX-0131, which is entering IND-enabling studies. The company's fourth drug candidate, TPX-0131 is a preclinical ALK inhibitor.